Multiple Myeloma Clinical Trial

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Summary

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable disease (according to IMWG diagnostic criteria.)
Received at least 3 prior MM treatment lines of therapy which must include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody as part of a prior line of therapy, either in monotherapy or in combination.
Eastern Cooperative Oncology Group performance status grade of 0 or 1.
Adequate hematologic, renal, hepatic, pulmonary, and cardiac function.

Exclusion Criteria:

Prior treatment with CAR-T cell therapy directed at any target.
Autologous stem cell transplant within the last 6 weeks before lymphodepletion.
Allogeneic stem cell transplant within 6 months before lymphodepletion.
Known active or prior history of CNS involvement.
Stroke or seizure within 6 months of signing ICF.
Seropositive for or history of human immunodeficiency virus.
Vaccinated with live, attenuated vaccine within 4 weeks prior to lymphodepletion.
Hepatitis B infection.
Hepatitis C infection.
Known life-threatening allergies, hypersensitivity, or intolerance to CB-011 or its excipients.

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

50

Study ID:

NCT05722418

Recruitment Status:

Recruiting

Sponsor:

Caribou Biosciences, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 18 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States More Info
Luciano Costa, MD
Contact
205-975-3371
[email protected]
CU Anschutz Medical Campus, Anshutz Cancer Pavillion
Aurora Colorado, 80045, United States More Info
Rona Wang
Contact
303-724-2703
[email protected]
Natalie Pfenning
Contact
303-724-9562
[email protected]
Daniel Sherbenou, MD, PhD
Principal Investigator
Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics
Miami Florida, 33136, United States More Info
Jay Spiegel, MD
Contact
305-243-0372
[email protected]
Jay Spiegel, MD
Principal Investigator
University of Kentucky/ Markey Cancer Center
Lexington Kentucky, 40536, United States More Info
Ashley Walton-Robbins
Contact
589-218-1758
[email protected]
Gregory Monohan, MD
Principal Investigator
Massachusetts General
Boston Massachusetts, 22007, United States More Info
Andrew Branagan, MD
Contact
617-724-4000
[email protected]
Andrew Branagan, MD
Principal Investigator
John Theurer Cancer Center at Hackensack UMC
Hackensack New Jersey, 07601, United States More Info
Palka Anand
Contact
551-996-8704
[email protected]
David Siegal, MD
Principal Investigator
Icahn School of Medicine at Mount Sinai
New York New York, 10029, United States More Info
Adriana Rossi, MD
Contact
917-828-3905
[email protected]
Adriana Rossi, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Sham Mailankody, MBBS
Contact
646-608-2091
[email protected]
Sham Mailankody, MBBS
Principal Investigator
Levine Cancer Institute
Charlotte North Carolina, 28204, United States More Info
Kelly Bumgarner
Contact
[email protected]
Manisha Bhutani, MD
Principal Investigator
Duke University Health System (DUHS)
Durham North Carolina, 27705, United States More Info
Matthew Fisher
Contact
919-668-1028
[email protected]
Cristina Gasparetto, MD
Principal Investigator
Oncology Hematology Care, Inc
Cincinnati Ohio, 45236, United States More Info
Doug Hart
Contact
[email protected]
James Essell, MD
Principal Investigator
Cleveland Clinic
Cleveland Ohio, 44195, United States More Info
Faiz Anwer, MD
Principal Investigator
Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States
University of Texas Southwestern Medical Center
Dallas Texas, 75390, United States More Info
Marcella Aguilar
Contact
[email protected]
Larry Anderson, MD
Principal Investigator
The University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Shiny Jayan
Contact
832-438-7390
[email protected]
Neeraj Saini, MD
Principal Investigator
Huntsman Cancer Institute, University of Utah
Salt Lake City Utah, 84112, United States More Info
Collind Boyington
Contact
801-587-4779
[email protected]
Douglas Sborov, MD
Principal Investigator
Virginia Commonwealth University
Richmond Virginia, 23235, United States More Info
Johanna Biamonte
Contact
804-628-1896
[email protected]
William Clark, MD
Principal Investigator
Froedtert and the Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Danielle King
Contact
414-805-9334
[email protected]
Binod Dhakal, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

50

Study ID:

NCT05722418

Recruitment Status:

Recruiting

Sponsor:


Caribou Biosciences, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.